Search the Newsreel

Eton Pharmaceuticals (NASDAQ:ETON) Shares Down 4.5% - Here's Why

Eton Pharmaceuticals (NASDAQ:ETON) saw its shares drop 4.5% on Tuesday, trading at $41.70 with significantly lower volume. Despite missing quarterly EPS estimates, the company exceeded revenue expectations, and analysts generally maintain a "Moderate Buy" rating with an average price target of $54.50. Recent insider …

Princeton Bancorp CIO Matthew Clark sells $59,904 in stock

Matthew T. Clark, CIO of Princeton Bancorp (NASDAQ:BPRN), sold 1,428 shares of company stock for $59,904 on August 6, 2026. This transaction leaves him with 0 directly owned shares. The sale occurred while the stock was trading near its 52-week high and is considered …

Princeton Bancorp (NASDAQ:BPRN) Insider Matthew Clark Sells 1,428 Shares

Princeton Bancorp insider Matthew Clark sold 1,428 shares of the company's stock, valued at approximately $59,905, reducing his position by 50%. The company recently reported strong quarterly earnings, beating analyst estimates, and declared a quarterly dividend of $0.35 per share. Analysts currently have a …

Princeton Bancorp (BPRN) CIO reports sale of 1,428 shares and small purchase

Princeton Bancorp's Chief Information Officer, Matthew T. Clark, recently engaged in mixed stock trades. He sold 1,428 shares of common stock at $41.95 per share on August 6, 2026, and previously purchased 71 shares at $36.20 per share on May 28, 2026, which included …

Eton Pharmaceuticals (ETON) Stock Could Be Pricey On A Very Large Three Year Run

Eton Pharmaceuticals (ETON) stock has seen significant long-term gains over the past three years but now appears expensive, passing only 2 of 6 valuation checks. The company trades at a P/S ratio of 14.6x, significantly higher than the industry average and its estimated fair …

Understanding the Setup: (BPRN) and Scalable Risk

This article analyzes Princeton Bancorp Inc Com (NASDAQ: BPRN), identifying a near-term neutral sentiment amidst mid and long-term strength. It presents AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths, support, and …

PRINCETON BANCORP Q2 NET INTEREST INCOME USD 20 MILLION

Princeton Bancorp reported a Q2 net interest income of $20 million. This financial update indicates the company's performance for the second quarter.

Princeton Bancorp Inc (BPRN) Stock News Today

This article provides current stock news for Princeton Bancorp Inc (BPRN), including its market performance and key financial metrics. As of the close on August 10, the stock was trading at $42.475, up 0.65%, with a market cap of $289.39 million. The platform indicates …

Heeton Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2026

Princeton Bancorp, Inc. Q2 2026: Revenue $31.66M, Net income $7.08M, EPS $1.04— 10-Q Summary

Princeton Bancorp, Inc. (BPRN) reported its second-quarter 2026 results, showing a significant rebound in profitability. The company posted revenue of $31.66 million, net income of $7.08 million, and diluted EPS of $1.04, compared to lower figures in the prior-year quarter. This recovery was driven …

Princeton Bancorp (Nasdaq: BPRN) reports $13.3M profit for first half 2026

Princeton Bancorp Inc (BPRN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Princeton Bancorp Inc (BPRN) has an earnings forecast score of 6.67, ranking 232 out of 395 in the Banking Services industry, with an average analyst price target of $34.25. Analysts currently have a "Hold" rating for the stock. The company's expected revenue for the …

ETON Q2'26 Earnings: revenue estimate is 27.11M USD

Eton Pharmaceuticals, Inc. (ETON) is scheduled to release its Q2'26 earnings on August 13, after market close at 4:05 PM ET (8:05 PM UTC). Analysts estimate revenue to be $27.11 million and earnings per share (EPS) at $0.16 for the quarter. The article provides …

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Recommendation of "Moderate Buy" by Brokerages

Eton Pharmaceuticals (NASDAQ:ETON) has received an average "Moderate Buy" rating from brokerages, with an average 12-month price target of $52.50. Despite company insiders selling approximately $4.85 million worth of shares, institutional investors have increased their stakes. The company's recent quarterly revenue exceeded expectations, but …

Don't Ignore The Insider Selling In Princeton Bancorp

A Vice Chairman at Princeton Bancorp recently sold US$364k worth of shares, representing 5.1% of their holding. While there were some insider purchases over the last year, the total value of shares sold by insiders was higher than shares bought. Despite growing earnings, the …

Eton Pharmaceuticals Promotes Radosavljevic to Chief Operating Officer

Eton Pharmaceuticals has promoted Danka Radosavljevic to Chief Operating Officer, recognizing her five years of service as Executive Vice President, Operations. Her new role includes an annual base salary of $520,800 and a discretionary incentive bonus, formalizing her expanded authority over daily operations and …

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Eton Pharmaceuticals has acquired the U.S. rights to ASN-001 (timolol topical gel) from Auson Pharmaceuticals, a late-stage product candidate for the treatment of proliferating superficial infantile hemangiomas. This acquisition complements Eton's existing product HEMANGEOL®, aiming to address a broader spectrum of infantile hemangioma patients, …

Eton Pharmaceuticals licenses ASN-001 for infantile hemangiomas

Eton Pharmaceuticals (NASDAQ: ETON) has licensed U.S. rights to ASN-001, a timolol topical gel for treating infantile hemangiomas, from Auson Pharmaceuticals. The company plans to submit a New Drug Application in the second half of 2027 following positive Phase II/III trial results showing significant …

Understanding the Setup: (ETON) and Scalable Risk

This article analyzes Eton Pharmaceuticals Inc. (NASDAQ: ETON), highlighting weak near-term sentiment but significant upside potential due to a lack of resistance above its current price. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, and provides a …

Eton will take emailed investor questions during Aug. 13 call

Eton Pharmaceuticals (NASDAQ: ETON) announced it will report its second-quarter 2026 financial results on Thursday, August 13, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET (3:30 p.m. CT) to discuss the results and will accept investor questions …

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Eton Pharmaceuticals has announced it will report its second-quarter 2026 financial results on Thursday, August 13, 2026. The company will also host a conference call and webcast to discuss these results and provide a business update.

Eton Pharmaceuticals (ETON) Files For Pediatric Label Expansion, Is The Stock Fully Priced?

Princeton Bancorp director Stephen Distler sells $364k in stock

Princeton Bancorp director Stephen Distler sold 8,776 shares of company stock worth $364,029 on July 31, 2026. This transaction leaves him with 83,220 directly held shares, with additional indirect holdings. The sale occurred while the stock trades near its 52-week high, having delivered a …

Form 4 Princeton Bancorp Inc For: 3 August By Investing.com

This article from Investing.com reports on a Form 4 filing for Princeton Bancorp Inc. on August 3rd. It includes the stock symbol BPRN and its current performance (+2.81%). The piece is concise, providing only the essential information about the Form 4.

Eton Gains on Acquiring Right to Baby Medicine

Eton Pharmaceuticals (NASDAQ: ETON) has acquired the U.S. commercialization rights to HEMANGEOL® oral solution, an Orphan Drug for infantile hemangioma, from Pierre Fabre Medicament Sas. This acquisition, combined with the recent approval of DESMODA™, brings Eton's commercial product portfolio to ten, reinforcing its focus …

Princeton Bancorp (BPRN) director sells 8,776 shares in July 31 trade

Princeton Bancorp director Stephen Distler sold 8,776 shares of common stock on July 31, 2026, at an average price of $41.4801 per share. Following this transaction, Distler directly holds 83,220 shares and has indirect holdings of 33,446 shares through a Family Limited Partnership and …

Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Down 4.6% - Time to Sell?

Princeton Bancorp Inc (BPRN) Institutional Confidence

Princeton Bancorp Inc (BPRN) has an institutional shareholding score of 3.00, placing it 250th out of 395 in the Banking Services industry. The institutional shareholding proportion is 43.66%, a 6.90% decrease quarter-over-quarter. Bill Nygren (OAKMX) is the largest institutional shareholder, holding 1.18% of shares …

Princeton Bancorp, Inc. SEC Filing (Jul 31, 2026)

This article reports on a Form 144 SEC filing by Princeton Bancorp, Inc. (BPRN) on July 31, 2026. The filing indicates a proposed sale of 10,000 shares of common stock with an aggregate market value of $411,700, acquired via private purchase in 2017. The …

Eton Pharmaceuticals Inc (ETON) Shares Fall 5.3% -- GF Value Says Still Overvalued

Eton Pharmaceuticals Inc (ETON) shares recently fell by 5.3%, making the stock significantly overvalued according to GuruFocus' GF Value™ estimate. The company, which is unprofitable, has a GF Score™ of 57/100, indicating average performance with strong growth potential but very poor valuation and momentum …

Is Eton Pharmaceuticals (ETON) Quietly Reframing Its Orphan-Drug Strategy With KHINDIVI’s Label Expansion Bid?

Eton Pharmaceuticals (ETON) has filed to expand the label for its hydrocortisone oral solution, KHINDIVI, to include younger pediatric patients with adrenocortical insufficiency. This move aims to broaden treatment options for a rare disease population, potentially impacting Eton's orphan-therapy investment narrative and future revenue …

Eton Pharmaceuticals (ETON) Projected to Announce Quarterly Earnings on Thursday

Eton Pharmaceuticals (NASDAQ:ETON) is expected to announce its Q2 2026 earnings on Thursday, August 6th, with analysts projecting earnings of $0.13 per share and revenue of $27.1130 million. The company reported a miss in its previous quarter with $0.05 EPS against an estimated $0.10. …

Duketon Mining (ASX:DKM): Barlee Gold Drilling and Exploration Outlook

Princeton Bancorp Inc (BPRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Princeton Bancorp Inc (BPRN), focusing on its support and resistance levels, various technical indicators, and moving averages. Princeton Bancorp Inc's current price momentum score is 3.97, placing it 56th out of 394 in the Banking Services industry, …

Analysts Expect Eton Pharmaceuticals, Inc. (NASDAQ:ETON) To Breakeven Soon

Analysts are optimistic about Eton Pharmaceuticals (NASDAQ: ETON) achieving breakeven soon, driven by strong growth in its pharmaceutical products. The company is projected to reach profitability by 2027, with revenue expected to increase significantly over the next few years. Despite a recent dip in …

Princeton Bancorp Inc (BPRN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Princeton Bancorp Inc (BPRN), noting its current valuation score of 9.21, ranking 61st in the Banking Services industry. The company's P/E ratio is 14.50, significantly below its recent high but above its recent low. Key valuation metrics …